<DOC>
	<DOCNO>NCT00875004</DOCNO>
	<brief_summary>RATIONALE : Epoetin beta may cause body make red blood cell may prevent reduce side effect patient undergo chemotherapy solid tumor . PURPOSE : This clinical trial study well epoetin beta work patient undergo chemotherapy solid tumor .</brief_summary>
	<brief_title>Epoetin Beta Patients Undergoing Chemotherapy Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Identify factor predictive treatment failure patient solid tumor treat epoetin beta undergo chemotherapy . Secondary - Evaluate impact achieve target hemoglobin level ( i.e. , hemoglobin &gt; 11 g/dL ) 8 week treatment epoetin beta . - Evaluate change hemoglobin level baseline 8 week treatment epoetin beta . - Evaluate tolerability epoetin beta patient . - Evaluate quality life patient . OUTLINE : This multicenter study . Patients receive epoetin beta subcutaneously week ≥ 8 week absence disease progression unacceptable toxicity . Patients complete quality-of-life questionnaire ( FACT-An ) baseline 8 week treatment .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor Hemoglobin 911 g/dL Planning receive epoetin beta ≥ 8 week undergoing chemotherapy cancer PATIENT CHARACTERISTICS : WHO performance status 02 Not pregnant nursing Not incarcerate guardianship No psychological , familial , social , geographical reason would preclude study followup PRIOR CONCURRENT THERAPY : See Disease Characteristics More 6 month since prior epoetin No concurrent chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>anemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>